Company / PP&E (Net)
Amgen PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.9B
FY2025
5-year range
$5.2B / $7.9B
FY2021-FY2025
Trend
+20.9%
vs FY2024
Sector context
#5 of 195
Health Care
What the data says
Among 195 Health Care companies, Amgen is in the top 3% for pp&e (net). PP&E (Net) has increased for 5 consecutive years, from $4.9B in FY2020 to $7.9B in FY2025.
Based on SEC 10-K filings.
$7.9B in FY2025 with a 5-year CAGR of +10.1%. Top quartile in the Health Care sector.
Improved from $5.9B to $7.9B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +13.4%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 195This company $7.9B Sector average $770.1M
▼
+927.5% above sector average
Key checks
Key Insights
- Amgen's pp&e (net) has grown for 5 consecutive years.
- 5-year CAGR of +10.1%, indicating consistent growth.
- In FY2025, pp&e (net) increased 20.9% year-over-year.
- Ranks #5 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.9B | +20.9% |
| FY2024 | $6.5B | +10.1% |
| FY2023 | $5.9B | +9.5% |
| FY2022 | $5.4B | +4.7% |
| FY2021 | $5.2B | +6.0% |
| FY2020 | $4.9B | -0.8% |
| FY2019 | $4.9B | -0.6% |
| FY2018 | $5.0B | -0.6% |
| FY2017 | $5.0B | +0.6% |
| FY2016 | $5.0B | +1.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026